By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Hutchison China MediTech (Chi-Med) 

21st Floor, Hutchison House
10 Harcourt Road
Hong Kong      China
Phone: 852-2121-8200 Fax: 852-2121-8281


SEARCH JOBS


Industry
Pharmaceutical






Company News
Hutchison China MediTech (Chi-Med) Earns $10 Million Milestone From AstraZeneca PLC (AZN) In Lung Cancer Trial 6/21/2016 2:58:31 PM
Hutchison China MediTech (Chi-Med) Release: Savolitinib Global Phase II Trial Initiated In EGFR Mutant Non-Small Cell Lung Cancer 6/20/2016 11:06:20 AM
Hutchison China MediTech (Chi-Med) Webcast Presentation Now Available For On-Demand Viewing: dbVIC - Deutsche Bank (DB) ADR Virtual Investor Conference 6/14/2016 11:29:52 AM
Hutchison China MediTech (Chi-Med) To Present At The dbVIC - Deutsche Bank (DB) ADR Virtual Investor Conference On June 10, 2016 6/6/2016 12:51:19 PM
Hutchison China MediTech (Chi-Med) Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib in Colorectal Cancer 5/13/2016 8:37:38 AM
Hutchison China MediTech (Chi-Med) To Participate In Two Healthcare Investor Conferences In May 5/3/2016 11:13:30 AM
Hutchison China MediTech (Chi-Med) Announces Exercise Of Overallotment Option 4/13/2016 10:43:35 AM
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689 4/12/2016 9:45:18 AM
Hutchison China MediTech (Chi-Med) Announces Closing Of U.S. Public Offering Of Adss Raising Approximately US$101 Million On The Nasdaq Stock Market 3/22/2016 8:38:05 AM
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients 3/21/2016 10:45:53 AM
12345
//-->